BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35241290)

  • 1. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: A systematic review and meta-analysis.
    Lee E; Terhaar S; McDaniel L; Gorelik D; Gerhard E; Chen C; Ma Y; Joshi AS; Goodman JF; Thakkar PG
    Am J Otolaryngol; 2022; 43(3):103394. PubMed ID: 35241290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
    Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
    Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 6. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 8. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
    Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.
    DiGennaro C; Vahdatzad V; Jalali MS; Toumi A; Watson T; Gazelle GS; Mercaldo N; Lubitz CC
    Thyroid; 2022 Oct; 32(10):1144-1157. PubMed ID: 35999710
    [No Abstract]   [Full Text] [Related]  

  • 10. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
    Yang Z; Zhang T; Layfield L; Esebua M
    J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis.
    Vuong HG; Nguyen TPX; Hassell LA; Jung CK
    Cancer Cytopathol; 2021 Mar; 129(3):182-189. PubMed ID: 32726885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
    Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
    San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of Afirma Gene Expression Classifier, Afirma Gene Sequencing Classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis.
    Vardarli I; Tan S; Görges R; Krämer BK; Herrmann K; Brochhausen C
    Endocr Connect; 2024 May; ():. PubMed ID: 38771544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign call rate and molecular test result distribution of ThyroSeq v3.
    Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
    Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
    Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
    Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Diagnostic Performance of Afirma Gene Expression Classifier for the Indeterminate Thyroid Nodules: A Meta-Analysis.
    Liu Y; Pan B; Xu L; Fang D; Ma X; Lu H
    Biomed Res Int; 2019; 2019():7150527. PubMed ID: 31531363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.